Physician profile
Frank J Perrone
NPI 1750345880
$2,651.74
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $943 · 2021: $464.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $405.49 | 2019-2021 | |
| Amarin Pharma, INC. | $276.38 | 2019-2021 | |
| Pfizer INC. | $258.28 | 2019-2021 | |
| Novo Nordisk INC | $235.56 | 2019-2020 | |
| Allergan, INC. | $164.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $162.05 | 2019-2020 | |
| Amgen INC. | $154.79 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $140.78 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.77 | 2019-2021 | |
| Abbvie INC. | $113.15 | 2021 | |
| Novartis Pharmaceuticals Corporation | $100.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.59 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $61.54 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $54.76 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $53.60 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $44.75 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $44.62 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $33.35 | 2021 | |
| Lilly USA, LLC | $27.49 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.48 | 2019 | |
| Althera Pharmaceuticals LLC | $18.07 | 2021 | |
| Janssen Biotech, INC. | $14.10 | 2019 | |
| Eisai INC. | $12.57 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Perrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.